Pfizer updates guidance, expects diluted EPS to be $1.29-$1.38
On September 3, 2015, Pfizer completed the acquisition of Hospira. Pfizer's fiscal year-end for international subsidiaries is November 30, 2015, and Pfizer's fiscal year-end for U.S. subsidiaries is December 31, 2015.
Consequently, Pfizer's 2015 financial results will include approximately three months of legacy Hospira international operations and approximately four months of legacy Hospira U.S. operations.
Financial results for Pfizer's third-quarter 2015 and nine-months ended September 27, 2015 will reflect approximately one month of legacy Hospira U.S. operations but will not include financial results from legacy Hospira international operations.
The ranges for certain components of Pfizer's 2015 financial guidance are: reported revenues $46.5 to $47.5 billion (previously $45 to $46 billion), reported diluted EPS $1.29 to $1.38 (previously $1.38 to $1.47), and adjusted diluted EPS $2.04 to $2.10 (previously $2.01 to $2.07). ■